RxDoctor Payments Data
★ My doctorsLook up a doctor →

Fred Cushner, MD

Orthopaedic Surgery · New York, NYNPI 1588637938

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $3,599,222 of the $4,420,193 with a category attached, or 81.4%. Smith+Nephew accounts for 87.8% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $1,557,213, 2.2 times the $698,459 reported in 2019. Among orthopaedic surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,420,193in general payments, 2019–2025

Across 568 payments — averaging $7782.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$3.9M
  • Orthalign Inc$440K
  • KCI USA, Inc.$93K
  • Acelrx Pharmaceuticals, Inc.$2K
  • Bioventus LLC$1K
  • Bioness Inc$1K
  • plus $1K from 4 others
$26,194in research payments, 2019–2025

Across 2 payments — averaging $13,097 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Smith+Nephew$26K

What the payments were for

  • Royalty or licence$3,599,22281%
  • Consulting fees$405,9569%
  • Speaking & faculty fees$273,4546%
  • Travel & lodging$123,8093%
  • Food & beverage$16,7030%
  • Education$1,0500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Smith+Nephew480$3,881,776
Orthalign Inc37$439,650
KCI USA, Inc.34$93,117
Acelrx Pharmaceuticals, Inc.1$2,000
Bioventus LLC1$1,400
Bioness Inc1$1,050
Zimmer Biomet8$903
Medtronic3$208
Stryker2$76
Johnson & Johnson1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,420,193 in reported general payments places this provider in the 95th percentile of 1,079 orthopaedic surgery providers in New York.

See all orthopaedic surgery providers in New York →

Medicare billing

Part B allowed, 2024
$438,211
Medicare patients
599
Services billed
6,960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib33$1,659
Diclofenac Sodium130$1,193
Oxycodone Hcl12$81

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →